FutureChem Co.,Ltd (KOSDAQ:220100)
South Korea flag South Korea · Delayed Price · Currency is KRW
18,130
-10 (-0.06%)
Aug 8, 2025, 3:30 PM KST
-0.06%
Market Cap400.84B
Revenue (ttm)18.93B
Net Income (ttm)-9.99B
Shares Out22.10M
EPS (ttm)-452.27
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume60,590
Average Volume215,829
Open18,400
Previous Close18,140
Day's Range18,000 - 18,400
52-Week Range14,900 - 31,250
Beta1.44
RSI52.55
Earnings DateAug 14, 2025

About Verve Therapeutics

FutureChem Co.,Ltd engages in the research and development, production, and sale of chemicals, pharmaceuticals, and medical devices in South Korea and internationally. The company offers radioactive pharmaceuticals, including [18F]FDG for the treatment of general cancer diagnosis, PDvue for Parkinson's disease, Alzavue for Alzheimer's disease, and FLT for the lung cancer diagnosis. Its products in pipeline include [18F]FC303, [177Lu]FC705, and 225Ac for the treatment of prostate cancer; F-FMT for brain tumor diagnosis; FC-505 for the treatment ... [Read more]

Sector Healthcare
Founded 1999
Employees 68
Stock Exchange KOSDAQ
Ticker Symbol 220100
Full Company Profile

Financial Performance

In 2024, FutureChem Co.,Ltd's revenue was 17.29 billion, an increase of 23.81% compared to the previous year's 13.97 billion. Losses were -9.42 billion, 40.4% more than in 2023.

Financial Statements

News

There is no news available yet.